Poster
AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET Fusion+ Advanced/Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Author
Benjamin Besse
Condition
Non-Small-Cell Lung Cancer
Drug target
RET fusions
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-ASCO-2020-Pralsetinib-AcceleRET-NSCLC-Poster.pdf
4 organizations
1 product
Product
PralsetinibOrganization
Blueprint MedicinesOrganization
Gustave Roussy, Villejuif, FranceOrganization
Vall d’Hebron University Hospital/VHIOOrganization
The Royal Marsden Hospital